Purdue to pay $8.3bn after admitting criminal charges in opioid caseAfter years of legal wrangling, Purdue Pharma has agreed a deal to resolve litigation about its role in Share XPurdue to pay $8.3bn after admitting criminal charges in opioid casehttps://pharmaphorum.com/news/purdue-to-pay-8-3bn-after-admitting-criminal-charges-in-opioid-case/
J&J settles Ohio lawsuits for $20m as opioid litigation train rumbles onJohnson & Johnson has managed to put opioid litigation in Ohio behind it with a $20 million settlement, Share XJ&J settles Ohio lawsuits for $20m as opioid litigation train rumbles onhttps://pharmaphorum.com/news/jj-settles-ohio-lawsuits-for-20m-as-opioid-litigation-train-rumbles-on/
Purdue presses ahead with bankruptcy filingAs expected, Purdue Pharma has formally filed for bankruptcy protection as it tries to resolve thousands of lawsuits Share XPurdue presses ahead with bankruptcy filinghttps://pharmaphorum.com/news/purdue-presses-ahead-with-bankruptcy-filing/
Purdue’s opioid settlement bid splits US statesPurdue Pharma’s multibillion-dollar bid to settle litigation over its involvement in the opioid crisis in the US is Share XPurdue’s opioid settlement bid splits US stateshttps://pharmaphorum.com/news/purdues-opioid-settlement-bid-splits-us-states/
Purdue preps bankruptcy as opioid settlement bid stumbles; reportPurdue Pharma is reported to be preparing to file for bankruptcy amid resistance to its $10-$12 billion offer Share XPurdue preps bankruptcy as opioid settlement bid stumbles; reporthttps://pharmaphorum.com/news/purdue-preps-bankruptcy-as-opioid-settlement-bid-stumbles-report/
Purdue said to be offering up to $12bn to settle opioid lawsuitsPurdue Pharma is preparing to make a $10 to $12 billion offer to settle more than 2,000 lawsuits Share XPurdue said to be offering up to $12bn to settle opioid lawsuitshttps://pharmaphorum.com/news/purdue-said-to-be-offering-up-to-12bn-to-settle-opioid-lawsuits/
As market declines, Purdue hopes to kick opiate habitAmid opiate crisis, Purdue looks for abuse-deterrent alternatives. Share XAs market declines, Purdue hopes to kick opiate habithttps://pharmaphorum.com/news/purdue/